SynthesisHelicobacter2009
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.
Synthesis in Helicobacter, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 80 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication
Who cites it
80 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.World journal of gastroenterology · 2016Pooled it
- Evidence-based clinical practice guidelines for peptic ulcer disease 2015.Journal of gastroenterology · 2016Guideline
- Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Optimum duration of regimens for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2013Pooled it
- [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].Atencion primaria · 2012Guideline
- Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.BMC infectious diseases · 2021Trial
- A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.Antimicrobial agents and chemotherapy · 2017Trial
- Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.Bosnian journal of basic medical sciences · 2016Trial
- Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.World journal of gastroenterology · 2015Trial
- Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.BioMed research international · 2015Trial
- Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.Antimicrobial agents and chemotherapy · 2014Trial
- Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.European journal of clinical pharmacology · 2013Trial
- Trial
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.Lancet (London, England) · 2011Trial
- Trial
- Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2010Trial
- Crises in Antimicrobial Stewardship: Misuse of Clarithromycin forPharmacoepidemiology · 2024Article
- Review
- Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication ofJournal of personalized medicine · 2021Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLow success rates with triple therapy for Helicobacter pylori infections have prompted search for alternatives. In one, a proton-pump inhibitor (PPI) and amoxicillin was followed by the PPI plus clarithromycin and a nitroimidazole (sequential therapy); in another, these four drugs were given concomitantly (concomitant therapy).
aimTo compare concomitant therapy with standard triple therapy for H. pylori infection.
methodsBy searching PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and abstracts of major gastrointestinal meeting, two independent reviewers systemically identified randomized controlled trials (RCT) comparing concomitant quadruple to standard triple therapies as well as studies reporting eradication rates of concomitant quadruple therapy in treatment of H. pylori. Pooled eradication rates and odds ratios (OR) with 95% confidence intervals (CI) were calculated, and univariable metaregression analysis for all extracted variables was conducted.
resultsWe identified nine studies (10 treatment arms) including five qualifying RCTs (576 subjects) comparing concomitant (293 subjects, duration 3 to 5 days) and triple therapy (283 subjects, duration 5 to 10 days) and four other studies evaluating concomitant therapy (478 subjects, duration 3 to 7 days). Pooled estimates of the five RCTs showed superiority of concomitant therapy over triple therapy; with intention-to-treat) pooled OR of 2.86 (95% CI: 1.73-4.73) and per-protocol (PP) pooled OR of 3.52 (95% CI: 1.95-6.38). Considering all 10 treatment arms, the ITT eradication rate was 89.7% (95% CI: 86.8-92.1%) and PP was 92.9% (95% CI: 90.2-94.8%).
conclusionConcomitant therapy appears to be an effective alternative to triple therapy and is less complex than sequential therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.